首页 > 最新文献

Blood Neoplasia最新文献

英文 中文
Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells 药理靶向 CBX7 可改变表观遗传格局并诱导白血病细胞分化
Pub Date : 2024-10-24 DOI: 10.1016/j.bneo.2024.100052
Anne P. de Groot , Chelsea R. Wilson , Ellen Weersing , Jacobine S. Pouw , Albertina Dethmers-Ausema , Huong Nguyen , Evan F. W. Chen , Alok Shaurya , Linda Smit , Fraser Hof , Gerald de Haan

Abstract

Self-renewal of leukemic cells results in the accumulation of dysfunctional blood cells and suppression of normal hematopoiesis. The polycomb group protein chromobox 7 (CBX7) is an epigenetic regulator that represses genes required for differentiation and cell cycle arrest and thereby promotes self-renewal. Because leukemic cells are highly self-renewing, we tested whether pharmacological targeting of CBX7 would reduce self-renewal and induce differentiation of human leukemic cells. We found that existing and newly developed CBX7 inhibitors derepress the epigenome, resulting in reduced ubiquitination of histone 2A and reduced binding of CBX7 to its target genes. This led to reduced cell growth, increased differentiation of leukemic cells in vitro, and delayed engraftment of primary leukemic cells in xenotransplant models. Therefore, pharmacological targeting of CBX7 constitutes a novel therapeutic approach for leukemia.
摘要 白血病细胞的自我更新会导致功能障碍血细胞的积累和正常造血的抑制。多聚酶群蛋白chromobox 7(CBX7)是一种表观遗传调节因子,可抑制分化和细胞周期停滞所需的基因,从而促进自我更新。由于白血病细胞具有很强的自我更新能力,我们测试了药理学靶向 CBX7 是否会减少人类白血病细胞的自我更新并诱导其分化。我们发现,现有的和新开发的 CBX7 抑制剂会抑制表观基因组,从而减少组蛋白 2A 的泛素化,并减少 CBX7 与其靶基因的结合。这导致体外细胞生长减少、白血病细胞分化增加,以及原发性白血病细胞在异种移植模型中的移植延迟。因此,以 CBX7 为药物靶点是治疗白血病的一种新方法。
{"title":"Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells","authors":"Anne P. de Groot ,&nbsp;Chelsea R. Wilson ,&nbsp;Ellen Weersing ,&nbsp;Jacobine S. Pouw ,&nbsp;Albertina Dethmers-Ausema ,&nbsp;Huong Nguyen ,&nbsp;Evan F. W. Chen ,&nbsp;Alok Shaurya ,&nbsp;Linda Smit ,&nbsp;Fraser Hof ,&nbsp;Gerald de Haan","doi":"10.1016/j.bneo.2024.100052","DOIUrl":"10.1016/j.bneo.2024.100052","url":null,"abstract":"<div><h3>Abstract</h3><div>Self-renewal of leukemic cells results in the accumulation of dysfunctional blood cells and suppression of normal hematopoiesis. The polycomb group protein chromobox 7 (CBX7) is an epigenetic regulator that represses genes required for differentiation and cell cycle arrest and thereby promotes self-renewal. Because leukemic cells are highly self-renewing, we tested whether pharmacological targeting of CBX7 would reduce self-renewal and induce differentiation of human leukemic cells. We found that existing and newly developed CBX7 inhibitors derepress the epigenome, resulting in reduced ubiquitination of histone 2A and reduced binding of CBX7 to its target genes. This led to reduced cell growth, increased differentiation of leukemic cells in vitro, and delayed engraftment of primary leukemic cells in xenotransplant models. Therefore, pharmacological targeting of CBX7 constitutes a novel therapeutic approach for leukemia.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma 多发性骨髓瘤患者对venetoclax反应的预测因素和CDK7抑制剂的治疗潜力
Pub Date : 2024-10-14 DOI: 10.1016/j.bneo.2024.100049
Rudra P. Dutta , Santiago Thibaud , Violetta Leshchenko , Meghana Ram , David T. Melnekoff , Sherry Bhalla , Paula Restrepo , Vikas A. Gupta , Benjamin G. Barwick , Scott Newman , Jonathan McCafferty , Feras Hantash , Ajay K. Nooka , Hearn J. Cho , Shambavi Richard , Cesar Rodriguez , Adriana Rossi , Larysa Sanchez , Ajai Chari , Lawrence H. Boise , Alessandro Laganà

Abstract

Venetoclax, a selective B-cell lymphoma 2 (BCL2) inhibitor, has emerged as a promising therapeutic agent for multiple myeloma (MM), particularly in patients harboring the t(11;14) translocation. In this study, we set out to identify markers of sensitivity and resistance to venetoclax in a real-world patient population, aiming to facilitate the development of personalized therapeutic strategies. Through the analysis of RNA sequencing (RNA-seq) data from relapsed/refractory patients treated with venetoclax, either as a single agent or in combination with other drugs, we unveiled a novel 6-gene signature that significantly stratified patients into risk groups for relapse and further validated its clinical relevance in 2 independent clinical and ex vivo data sets. Our analysis also highlighted the negative impact of chromosome 1q gain, which harbors the myeloid cell leukemia-1 (MCL1) gene, on progression-free survival, even in t(11;14)-positive patients. Encouraged by the well-documented role of MCL1 in resistance to venetoclax in various malignancies and the prognostic importance of the BCL2/MCL1 ratio in our cohort, we explored Cyclin-Dependent Kinase 7 (CDK7) inhibition as a potential strategy to overcome venetoclax resistance. In vitro experiments demonstrated that CRISPR-Cas9–mediated CDK7 depletion led to decreased MCL1 levels, enhancing the sensitivity of MM cells to venetoclax. Moreover, the combination of the CDK7 inhibitor THZ1 with venetoclax markedly induced cell death in venetoclax-resistant MM cells harboring 1q gain, thus offering a rational therapeutic approach, particularly for patients with this aberration. Overall, these findings provide important insights for optimizing venetoclax-based therapeutic strategies in MM.
摘要Venetoclax是一种选择性B细胞淋巴瘤2(BCL2)抑制剂,已成为治疗多发性骨髓瘤(MM)的一种有前途的药物,尤其是对携带t(11;14)易位的患者。在这项研究中,我们试图在现实世界的患者群体中找出对 venetoclax 敏感和耐药的标志物,以促进个性化治疗策略的开发。通过分析复发/难治患者的RNA测序(RNA-seq)数据,我们发现了一个新的6基因特征,它能显著地将患者分为复发风险组,并在2个独立的临床和体内外数据集中进一步验证了其临床相关性。我们的分析还强调了携带髓系细胞白血病-1(MCL1)基因的 1q 染色体增益对无进展生存期的负面影响,即使在 t(11;14)阳性患者中也是如此。在各种恶性肿瘤中,MCL1在文尼他克耐药中的作用已得到充分证实,而且在我们的队列中,BCL2/MCL1比值对预后具有重要意义,受此鼓舞,我们探索了抑制细胞周期蛋白依赖性激酶7(CDK7)作为克服文尼他克耐药的一种潜在策略。体外实验表明,CRISPR-Cas9介导的CDK7去除会导致MCL1水平下降,从而提高MM细胞对venetoclax的敏感性。此外,CDK7抑制剂THZ1与venetoclax联用可明显诱导携带1q增益的venetoclax耐药MM细胞死亡,从而提供了一种合理的治疗方法,尤其适用于有这种畸变的患者。总之,这些发现为优化基于文替可克的MM治疗策略提供了重要启示。
{"title":"Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma","authors":"Rudra P. Dutta ,&nbsp;Santiago Thibaud ,&nbsp;Violetta Leshchenko ,&nbsp;Meghana Ram ,&nbsp;David T. Melnekoff ,&nbsp;Sherry Bhalla ,&nbsp;Paula Restrepo ,&nbsp;Vikas A. Gupta ,&nbsp;Benjamin G. Barwick ,&nbsp;Scott Newman ,&nbsp;Jonathan McCafferty ,&nbsp;Feras Hantash ,&nbsp;Ajay K. Nooka ,&nbsp;Hearn J. Cho ,&nbsp;Shambavi Richard ,&nbsp;Cesar Rodriguez ,&nbsp;Adriana Rossi ,&nbsp;Larysa Sanchez ,&nbsp;Ajai Chari ,&nbsp;Lawrence H. Boise ,&nbsp;Alessandro Laganà","doi":"10.1016/j.bneo.2024.100049","DOIUrl":"10.1016/j.bneo.2024.100049","url":null,"abstract":"<div><h3>Abstract</h3><div>Venetoclax, a selective B-cell lymphoma 2 (BCL2) inhibitor, has emerged as a promising therapeutic agent for multiple myeloma (MM), particularly in patients harboring the t(11;14) translocation. In this study, we set out to identify markers of sensitivity and resistance to venetoclax in a real-world patient population, aiming to facilitate the development of personalized therapeutic strategies. Through the analysis of RNA sequencing (RNA-seq) data from relapsed/refractory patients treated with venetoclax, either as a single agent or in combination with other drugs, we unveiled a novel 6-gene signature that significantly stratified patients into risk groups for relapse and further validated its clinical relevance in 2 independent clinical and ex vivo data sets. Our analysis also highlighted the negative impact of chromosome 1q gain, which harbors the myeloid cell leukemia-1 (MCL1) gene, on progression-free survival, even in t(11;14)-positive patients. Encouraged by the well-documented role of MCL1 in resistance to venetoclax in various malignancies and the prognostic importance of the BCL2/MCL1 ratio in our cohort, we explored Cyclin-Dependent Kinase 7 (CDK7) inhibition as a potential strategy to overcome venetoclax resistance. In vitro experiments demonstrated that CRISPR-Cas9–mediated CDK7 depletion led to decreased MCL1 levels, enhancing the sensitivity of MM cells to venetoclax. Moreover, the combination of the CDK7 inhibitor THZ1 with venetoclax markedly induced cell death in venetoclax-resistant MM cells harboring 1q gain, thus offering a rational therapeutic approach, particularly for patients with this aberration. Overall, these findings provide important insights for optimizing venetoclax-based therapeutic strategies in MM.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies 针对 B 细胞恶性肿瘤的低亲和力人源化 CD19 嵌合抗原受体的开发与特性鉴定
Pub Date : 2024-10-13 DOI: 10.1016/j.bneo.2024.100048
Lawrence A. Stern ∗ , Vibhuti Vyas ∗ , Laura Lim , Christian Huynh , Ryan Urak , Ruby Espinosa , Zhiqiang Wang , Michalina Silva Thiel , John C. Williams , Stephen J. Forman , Christine E. Brown † , Xiuli Wang †

Abstract

In this study, we aim to develop a humanized CD19 chimeric antigen receptor (CAR) that matches the potency of the FMC63 CAR and potentially reduces the risk of immunogenicity. The murine FMC63 single-chain variable fragment (scFv) was humanized yielding 2 lead candidate scFvs, VH4vκ1 and 4D5, which exhibit weaker binding affinity than FMC63 scFv. These humanized CD19-scFvs were incorporated into CAR constructs to generate huCD19R(VH4Vκ1) and huCD19R(4D5) CARs, both containing the 41BB costimulatory domain. The antitumor activity of the CAR T cells was assessed against CD19+ and CD19 low-expressing tumors. FMC63 CAR T cells with the same backbone in all studies were used as controls. The results showed that the huCD19R(VH4vκ1) CAR T cells exhibited similar expansion, phenotype, and effector function to the FMC63 CAR upon stimulation with CD19 targets. When the CAR T cells were challenged with CD19-bearing tumors, the huCD19R(VH4vκ1) CAR T cells showed similar proliferation to the FMC63 CAR T cells, whereas the huCD19R(4D5) CAR T cells essentially failed to proliferate. Moreover, the huCD19R(VH4vκ1) CAR T cells exhibited significantly better in vivo antitumor activity than the huCD19R(4D5) CAR T cells when tested against tumors expressing a range of CD19 antigens. Finally, using a hybrid model, we found that the huCD19R(VH4vκ1) T cells had a comparable cytokine secretion profile to that of FMC63 CAR T cells. Furthermore, the huCD19R(VH4vκ1) CAR T cells exhibited efficacy against both CD19+ and engineered CD19 low-expressing tumors. These findings suggest that huCD19R(VH4vκ1) CAR T cells may offer enhanced persistence and represent a promising candidate for clinical translation as a therapy for CD19+ tumors.
摘要 在本研究中,我们旨在开发一种人源化 CD19 嵌合抗原受体(CAR),其效力与 FMC63 CAR 相当,并可能降低免疫原性风险。对小鼠 FMC63 单链可变片段(scFv)进行了人源化处理,得到了两个主要候选 scFv:VH4vκ1 和 4D5,它们的结合亲和力比 FMC63 scFv 弱。这些人源化 CD19-scFv 被整合到 CAR 构建物中,生成了 huCD19R(VH4Vκ1) 和 huCD19R(4D5)CAR,这两种 CAR 都含有 41BB costimulatory domain。评估了 CAR T 细胞对 CD19+ 和 CD19 低表达肿瘤的抗肿瘤活性。所有研究中使用相同骨架的 FMC63 CAR T 细胞作为对照。结果显示,huCD19R(VH4vκ1) CAR T细胞在受到CD19靶点刺激时,表现出与FMC63 CAR相似的扩增、表型和效应功能。当 CAR T 细胞受到 CD19 肿瘤的挑战时,huCD19R(VH4vκ1) CAR T 细胞表现出与 FMC63 CAR T 细胞相似的增殖,而 huCD19R(4D5) CAR T 细胞基本上没有增殖。此外,在对表达一系列 CD19 抗原的肿瘤进行测试时,huCD19R(VH4vκ1) CAR T 细胞的体内抗肿瘤活性明显优于 huCD19R(4D5) CAR T 细胞。最后,我们利用混合模型发现,huCD19R(VH4vκ1) T细胞的细胞因子分泌情况与FMC63 CAR T细胞相当。此外,huCD19R(VH4vκ1) CAR T细胞对CD19+和低表达CD19的工程肿瘤都有疗效。这些研究结果表明,huCD19R(VH4vκ1)CAR T细胞可能具有更强的持久性,有望作为CD19+肿瘤的治疗方法应用于临床。
{"title":"Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies","authors":"Lawrence A. Stern ∗ ,&nbsp;Vibhuti Vyas ∗ ,&nbsp;Laura Lim ,&nbsp;Christian Huynh ,&nbsp;Ryan Urak ,&nbsp;Ruby Espinosa ,&nbsp;Zhiqiang Wang ,&nbsp;Michalina Silva Thiel ,&nbsp;John C. Williams ,&nbsp;Stephen J. Forman ,&nbsp;Christine E. Brown † ,&nbsp;Xiuli Wang †","doi":"10.1016/j.bneo.2024.100048","DOIUrl":"10.1016/j.bneo.2024.100048","url":null,"abstract":"<div><h3>Abstract</h3><div>In this study, we aim to develop a humanized CD19 chimeric antigen receptor (CAR) that matches the potency of the FMC63 CAR and potentially reduces the risk of immunogenicity. The murine FMC63 single-chain variable fragment (scFv) was humanized yielding 2 lead candidate scFvs, VH4vκ1 and 4D5, which exhibit weaker binding affinity than FMC63 scFv. These humanized CD19-scFvs were incorporated into CAR constructs to generate huCD19R(VH4Vκ1) and huCD19R(4D5) CARs, both containing the 41BB costimulatory domain. The antitumor activity of the CAR T cells was assessed against CD19<sup>+</sup> and CD19 low-expressing tumors. FMC63 CAR T cells with the same backbone in all studies were used as controls. The results showed that the huCD19R(VH4vκ1) CAR T cells exhibited similar expansion, phenotype, and effector function to the FMC63 CAR upon stimulation with CD19 targets. When the CAR T cells were challenged with CD19-bearing tumors, the huCD19R(VH4vκ1) CAR T cells showed similar proliferation to the FMC63 CAR T cells, whereas the huCD19R(4D5) CAR T cells essentially failed to proliferate. Moreover, the huCD19R(VH4vκ1) CAR T cells exhibited significantly better in vivo antitumor activity than the huCD19R(4D5) CAR T cells when tested against tumors expressing a range of CD19 antigens. Finally, using a hybrid model, we found that the huCD19R(VH4vκ1) T cells had a comparable cytokine secretion profile to that of FMC63 CAR T cells. Furthermore, the huCD19R(VH4vκ1) CAR T cells exhibited efficacy against both CD19<sup>+</sup> and engineered CD19 low-expressing tumors. These findings suggest that huCD19R(VH4vκ1) CAR T cells may offer enhanced persistence and represent a promising candidate for clinical translation as a therapy for CD19<sup>+</sup> tumors.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100048"},"PeriodicalIF":0.0,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling 解读MARCH5对多发性骨髓瘤的影响:自噬调控和AKT-FOXO3信号传导的启示
Pub Date : 2024-10-12 DOI: 10.1016/j.bneo.2024.100046
Hamed Bashiri , Ahad Khalilnezhad , Haruhito Totani , Joe Yeong , Tae-Hoon Chung , Felicia Wee , Yuezhen Xue , Zhen Wei Neo , Li Yen Chong , Wee Joo Chng , Atsushi Watanabe , Siok-Bian Ng , The Phyu , Toshio Suda

Abstract

Multiple myeloma (MM) stands as a formidable blood malignancy, necessitating innovative therapeutic approaches. Excessive immunoglobulin production within myeloma cells leads to a buildup of toxic proteins, and autophagy plays a crucial role in their survival by degrading toxic aggregates and generating energy. Membrane-associated RING finger protein 5 (MARCH5) is an E3-ligase positioned at the outer mitochondrial membrane and has been shown to regulate autophagy by competing for MicroRNA 30a (MIR30A). Given the fundamental significance of autophagy in promoting the survival of myeloma cells, coupled with the regulatory role of MARCH5 in autophagic activity, we hypothesized that MARCH5 plays an essential function in MM and holds a pivotal position in the pathogenesis and progression of MM. We identified MARCH5’s unique dependencies in MM cells by analyzing the Cancer Dependency Map, thereby establishing its significance in MM biology. Examining various data sets, including CoMMpass (Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Study) and HOVON (Haemato-Oncology Foundation for Adults in the Netherlands), demonstrated a correlation between MARCH5 expression and patient outcomes. Knockdown of MARCH5 revealed a substantial reduction in MM cell viability, which was associated with a decrease in autophagic activity. Mechanistically, we unraveled a novel MARCH5/AKT/FOXO3 axis, wherein MARCH5 regulates autophagy through the Protein Kinase B (AKT)-mediated degradation of Forkhead Box O3 (FOXO3). Compromised MM cell viability observed with MARCH5 knockdown was recapitulated in FOXO3 knockdown experiments, validating the pivotal role of FOXO3 in mediating MARCH5’s effects. In conclusion, this research highlights the crucial role of MARCH5 in MM, and the identified MARCH5/AKT/FOXO3 axis enhances our understanding of MM biology and provides a foundation for developing targeted therapies.
摘要多发性骨髓瘤(MM)是一种可怕的血液恶性肿瘤,需要创新的治疗方法。骨髓瘤细胞内过量的免疫球蛋白生成会导致有毒蛋白质的堆积,而自噬则通过降解有毒的聚集体并产生能量,在骨髓瘤细胞的存活过程中发挥着至关重要的作用。膜相关 RING 手指蛋白 5(MARCH5)是一种位于线粒体外膜的 E3 连接酶,已被证明可通过竞争 MicroRNA 30a (MIR30A)来调节自噬。鉴于自噬在促进骨髓瘤细胞存活方面的重要意义,以及 MARCH5 在自噬活动中的调控作用,我们推测 MARCH5 在 MM 中发挥着重要功能,并在 MM 的发病机制和进展中占据关键地位。我们通过分析癌症依赖性图谱(Cancer Dependency Map)确定了MARCH5在MM细胞中的独特依赖性,从而确立了它在MM生物学中的重要地位。通过研究各种数据集,包括CoMMpass(多发性骨髓瘤临床结果与遗传特征个人评估研究)和HOVON(荷兰成人血液肿瘤基金会),证明了MARCH5的表达与患者预后之间的相关性。敲除MARCH5后,MM细胞的存活率大大降低,这与自噬活性降低有关。从机理上讲,我们发现了一个新的MARCH5/AKT/FOXO3轴,其中MARCH5通过蛋白激酶B(AKT)介导的叉头框O3(FOXO3)降解来调节自噬。FOXO3敲除实验再现了MARCH5敲除时观察到的MM细胞活力下降,验证了FOXO3在介导MARCH5效应中的关键作用。总之,这项研究强调了 MARCH5 在 MM 中的关键作用,所确定的 MARCH5/AKT/FOXO3 轴增强了我们对 MM 生物学的了解,并为开发靶向疗法奠定了基础。
{"title":"Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling","authors":"Hamed Bashiri ,&nbsp;Ahad Khalilnezhad ,&nbsp;Haruhito Totani ,&nbsp;Joe Yeong ,&nbsp;Tae-Hoon Chung ,&nbsp;Felicia Wee ,&nbsp;Yuezhen Xue ,&nbsp;Zhen Wei Neo ,&nbsp;Li Yen Chong ,&nbsp;Wee Joo Chng ,&nbsp;Atsushi Watanabe ,&nbsp;Siok-Bian Ng ,&nbsp;The Phyu ,&nbsp;Toshio Suda","doi":"10.1016/j.bneo.2024.100046","DOIUrl":"10.1016/j.bneo.2024.100046","url":null,"abstract":"<div><h3>Abstract</h3><div>Multiple myeloma (MM) stands as a formidable blood malignancy, necessitating innovative therapeutic approaches. Excessive immunoglobulin production within myeloma cells leads to a buildup of toxic proteins, and autophagy plays a crucial role in their survival by degrading toxic aggregates and generating energy. Membrane-associated RING finger protein 5 (MARCH5) is an E3-ligase positioned at the outer mitochondrial membrane and has been shown to regulate autophagy by competing for MicroRNA 30a (MIR30A). Given the fundamental significance of autophagy in promoting the survival of myeloma cells, coupled with the regulatory role of MARCH5 in autophagic activity, we hypothesized that MARCH5 plays an essential function in MM and holds a pivotal position in the pathogenesis and progression of MM. We identified MARCH5’s unique dependencies in MM cells by analyzing the Cancer Dependency Map, thereby establishing its significance in MM biology. Examining various data sets, including CoMMpass (Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Study) and HOVON (Haemato-Oncology Foundation for Adults in the Netherlands), demonstrated a correlation between MARCH5 expression and patient outcomes. Knockdown of <em>MARCH5</em> revealed a substantial reduction in MM cell viability, which was associated with a decrease in autophagic activity. Mechanistically, we unraveled a novel MARCH5/AKT/FOXO3 axis, wherein MARCH5 regulates autophagy through the Protein Kinase B (AKT)-mediated degradation of Forkhead Box O3 (FOXO3). Compromised MM cell viability observed with <em>MARCH5</em> knockdown was recapitulated in <em>FOXO3</em> knockdown experiments, validating the pivotal role of FOXO3 in mediating MARCH5’s effects. In conclusion, this research highlights the crucial role of MARCH5 in MM, and the identified MARCH5/AKT/FOXO3 axis enhances our understanding of MM biology and provides a foundation for developing targeted therapies.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy 前线免疫化疗后滤泡性淋巴瘤高危定义事件的治疗结果
Pub Date : 2024-10-08 DOI: 10.1016/j.bneo.2024.100044
Joshua W. D. Tobin , Venkata A. Chikatamarla , Marko Matic , Alison Griffin , Rakin Chowdhury , Ross Salvaris , Amanda Goh , Harrison Black , Tsz Hung Tong , Callum Birks , Sanjiv Jain , Elizabeth Goodall , Shreerang Sirdesai , Thomas Trevis , Elizabeth Steinepreis , Yiyang Chen , Li Li , Glenn Broadby , Naadir Gutta , Kirk Morris , Greg Hapgood

Abstract

Progression of follicular lymphoma (FL) or transformation (TFL) within 24 months of immunochemotherapy (ICT) represent high-risk defining events (HRDE) with poor overall survival (OS). We examined baseline clinical characteristics, imaging, and outcomes for patients experiencing HRDE with newly diagnosed FL requiring ICT. HRDE groups were: relapse or progression of FL within 24 months (FL24), early TFL (transformation <24 months of ICT), late TFL (transformation >24 months of ICT).433 patients were categorized as reference FL (Ref FL), n = 352 (no HRDE); FL24, n = 43; early TFL, n = 29; late TFL, n = 9. Chemotherapy included bendamustine (63%), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) (27%), or CVP (cyclophosphamide, vincristine, prednisone) (10%); 85% received rituximab/15% obinutuzumab and 48% received maintenance therapy. Compared with Ref FL group, OS from HRDE was inferior for FL24 (hazard ratio [HR], 3.93; 95% confidence interval [CI], 2.14-7.23), early TFL (HR, 8.16; 95% CI, 4.38-15.2), and late TFL (HR, 8.23; 95% CI, 3.18-21.25). OS from HRDE was inferior for early TFL compared with FL24 (HR, 2.08; 95% CI, 1.02-4.21). In multivariable analysis, performance status, lactate dehydrogenase, beta-2-microglobulin and grade 3A were associated with early TFL. Clinical characteristics did not differentiate early TFL from FL24. Maximum standardized uptake value was higher in early TFL but not FL24 compared to Ref FL. Early TFL and FL24 represent different HRDEs and are associated with inferior OS. Distinguishing early TFL from FL24 is important for biomarker development, management and to develop and interpret trials in this area of unmet need.
摘要 免疫化疗(ICT)后24个月内滤泡性淋巴瘤(FL)进展或转化(TFL)是高危定义事件(HRDE),总生存率(OS)很低。我们研究了新确诊FL并需要接受ICT治疗的HRDE患者的基线临床特征、影像学检查和预后。HRDE组为:24个月内FL复发或进展(FL24)、早期TFL(ICT 24个月后转化)、晚期TFL(ICT 24个月后转化)。433例患者被分为参考FL(Ref FL),n = 352(无HRDE);FL24,n = 43;早期TFL,n = 29;晚期TFL,n = 9。化疗包括苯达莫司汀(63%)、CHOP(环磷酰胺、长春新碱、多柔比星、泼尼松)(27%)或CVP(环磷酰胺、长春新碱、泼尼松)(10%);85%接受利妥昔单抗/15%接受奥比妥珠单抗治疗,48%接受维持治疗。与 Ref FL 组相比,HRDE 的 OS 不如 FL24(危险比 [HR],3.93;95% 置信区间 [CI],2.14-7.23)、早期 TFL(HR,8.16;95% CI,4.38-15.2)和晚期 TFL(HR,8.23;95% CI,3.18-21.25)。早期TFL与FL24相比,HRDE的OS较低(HR,2.08;95% CI,1.02-4.21)。在多变量分析中,表现状态、乳酸脱氢酶、β-2-微球蛋白和3A级与早期TFL相关。临床特征并不能区分早期 TFL 和 FL24。与参考 FL 相比,早期 TFL 的最大标准化摄取值更高,而 FL24 则不高。早期TFL和FL24代表不同的HRDE,与较差的OS相关。区分早期TFL和FL24对于生物标志物的开发、管理以及在这一未满足需求领域开展和解释试验非常重要。
{"title":"Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy","authors":"Joshua W. D. Tobin ,&nbsp;Venkata A. Chikatamarla ,&nbsp;Marko Matic ,&nbsp;Alison Griffin ,&nbsp;Rakin Chowdhury ,&nbsp;Ross Salvaris ,&nbsp;Amanda Goh ,&nbsp;Harrison Black ,&nbsp;Tsz Hung Tong ,&nbsp;Callum Birks ,&nbsp;Sanjiv Jain ,&nbsp;Elizabeth Goodall ,&nbsp;Shreerang Sirdesai ,&nbsp;Thomas Trevis ,&nbsp;Elizabeth Steinepreis ,&nbsp;Yiyang Chen ,&nbsp;Li Li ,&nbsp;Glenn Broadby ,&nbsp;Naadir Gutta ,&nbsp;Kirk Morris ,&nbsp;Greg Hapgood","doi":"10.1016/j.bneo.2024.100044","DOIUrl":"10.1016/j.bneo.2024.100044","url":null,"abstract":"<div><h3>Abstract</h3><div>Progression of follicular lymphoma (FL) or transformation (TFL) within 24 months of immunochemotherapy (ICT) represent high-risk defining events (HRDE) with poor overall survival (OS). We examined baseline clinical characteristics, imaging, and outcomes for patients experiencing HRDE with newly diagnosed FL requiring ICT. HRDE groups were: relapse or progression of FL within 24 months (FL24), early TFL (transformation &lt;24 months of ICT), late TFL (transformation &gt;24 months of ICT).433 patients were categorized as reference FL (Ref FL), n = 352 (no HRDE); FL24, n = 43; early TFL, n = 29; late TFL, n = 9. Chemotherapy included bendamustine (63%), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) (27%), or CVP (cyclophosphamide, vincristine, prednisone) (10%); 85% received rituximab/15% obinutuzumab and 48% received maintenance therapy. Compared with Ref FL group, OS from HRDE was inferior for FL24 (hazard ratio [HR], 3.93; 95% confidence interval [CI], 2.14-7.23), early TFL (HR, 8.16; 95% CI, 4.38-15.2), and late TFL (HR, 8.23; 95% CI, 3.18-21.25). OS from HRDE was inferior for early TFL compared with FL24 (HR, 2.08; 95% CI, 1.02-4.21). In multivariable analysis, performance status, lactate dehydrogenase, beta-2-microglobulin and grade 3A were associated with early TFL. Clinical characteristics did not differentiate early TFL from FL24. Maximum standardized uptake value was higher in early TFL but not FL24 compared to Ref FL. Early TFL and FL24 represent different HRDEs and are associated with inferior OS. Distinguishing early TFL from FL24 is important for biomarker development, management and to develop and interpret trials in this area of unmet need.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma 针对复发性/难治性多发性骨髓瘤患者的抗CD38抗体美扎吉他单抗1b期研究
Pub Date : 2024-09-18 DOI: 10.1016/j.bneo.2024.100043
Amrita Y. Krishnan , Krina K. Patel , Meera Mohan , Sundar Jagannath , Ruben Niesvizky , Rebecca W. Silbermann , Ziji Yu , Tao Long , Scott R. P. McDonnell , Deborah Berg , Keith E. Stockerl-Goldstein

Abstract

This phase 1b trial aimed to determine the safety, tolerability, and preliminary efficacy of mezagitamab, a subcutaneously administered anti-CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Eligible patients had received ≥3 prior lines of treatment, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and a steroid, or ≥2 prior lines in which 1 included a PI + IMiD, and were refractory or intolerant to ≥1 IMiD and ≥1 PI. Fifty patients were enrolled: 44 received mezagitamab monotherapy (dose-escalating cohorts at 45-1200 mg) and 6 received mezagitamab 300 mg in combination with pomalidomide plus dexamethasone. Patients received mezagitamab weekly for 8 doses, every other week for 8 doses, and monthly thereafter. No dose-limiting toxicities were reported with single-agent mezagitamab, and the recommended phase 2 dose was determined as 600 mg. The most common drug-related treatment-emergent adverse events (TEAEs) were fatigue in the monotherapy cohort (9/44 patients) and neutropenia in the combination cohort (4/6 patients); neutropenia was the only drug-related grade ≥3 TEAE to occur in >1 patient. No infusion reactions occurred, and 4 injection-site reactions were reported. Three patients discontinued treatment due to TEAEs. Among the 22 patients receiving 600 mg mezagitamab, the overall response rate was 47%, and the median duration of response was 22.1 months. Mezagitamab outcomes were comparable to those reported with other anti-CD38 therapies in patients with advanced RRMM. Further development of mezagitamab in myeloma is not planned, but studies are underway in autoimmune conditions. This trial was registered at www.ClinicalTrials.gov as #NCT03439280.
摘要这项1b期试验旨在确定复发性/难治性多发性骨髓瘤(RRMM)患者皮下注射抗CD38单克隆抗体mezagitamab的安全性、耐受性和初步疗效。符合条件的患者既往接受过≥3种治疗,包括一种免疫调节药物(IMiD)、一种蛋白酶体抑制剂(PI)和一种类固醇,或既往接受过≥2种治疗,其中1种包括PI+IMiD,并且对≥1种IMiD和≥1种PI难治或不耐受。50名患者入选:44名患者接受了麦扎吉单抗单药治疗(剂量递增组为45-1200毫克),6名患者接受了300毫克麦扎吉单抗联合泊马度胺加地塞米松治疗。患者每周接受一次麦扎吉单抗治疗,共8次,隔周一次,共8次,之后每月一次。单药麦扎吉单抗未出现剂量限制性毒性反应,第二阶段的推荐剂量被确定为600毫克。最常见的药物相关治疗突发不良事件(TEAEs)是单药治疗队列中的疲劳(9/44例患者)和联合治疗队列中的中性粒细胞减少症(4/6例患者);中性粒细胞减少症是唯一发生在>1例患者身上的药物相关≥3级TEAE。未发生输液反应,报告了4例注射部位反应。3名患者因出现TEAE而中断治疗。在接受600毫克美扎吉单抗治疗的22名患者中,总反应率为47%,中位反应持续时间为22.1个月。在晚期RRMM患者中,美扎吉单抗的疗效与其他抗CD38疗法的疗效相当。目前尚未计划在骨髓瘤领域进一步开发麦扎吉单抗,但正在进行自身免疫疾病的研究。该试验已在 www.ClinicalTrials.gov 注册,注册号为 #NCT03439280。
{"title":"Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma","authors":"Amrita Y. Krishnan ,&nbsp;Krina K. Patel ,&nbsp;Meera Mohan ,&nbsp;Sundar Jagannath ,&nbsp;Ruben Niesvizky ,&nbsp;Rebecca W. Silbermann ,&nbsp;Ziji Yu ,&nbsp;Tao Long ,&nbsp;Scott R. P. McDonnell ,&nbsp;Deborah Berg ,&nbsp;Keith E. Stockerl-Goldstein","doi":"10.1016/j.bneo.2024.100043","DOIUrl":"10.1016/j.bneo.2024.100043","url":null,"abstract":"<div><h3>Abstract</h3><div>This phase 1b trial aimed to determine the safety, tolerability, and preliminary efficacy of mezagitamab, a subcutaneously administered anti-CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Eligible patients had received ≥3 prior lines of treatment, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and a steroid, or ≥2 prior lines in which 1 included a PI + IMiD, and were refractory or intolerant to ≥1 IMiD and ≥1 PI. Fifty patients were enrolled: 44 received mezagitamab monotherapy (dose-escalating cohorts at 45-1200 mg) and 6 received mezagitamab 300 mg in combination with pomalidomide plus dexamethasone. Patients received mezagitamab weekly for 8 doses, every other week for 8 doses, and monthly thereafter. No dose-limiting toxicities were reported with single-agent mezagitamab, and the recommended phase 2 dose was determined as 600 mg. The most common drug-related treatment-emergent adverse events (TEAEs) were fatigue in the monotherapy cohort (9/44 patients) and neutropenia in the combination cohort (4/6 patients); neutropenia was the only drug-related grade ≥3 TEAE to occur in &gt;1 patient. No infusion reactions occurred, and 4 injection-site reactions were reported. Three patients discontinued treatment due to TEAEs. Among the 22 patients receiving 600 mg mezagitamab, the overall response rate was 47%, and the median duration of response was 22.1 months. Mezagitamab outcomes were comparable to those reported with other anti-CD38 therapies in patients with advanced RRMM. Further development of mezagitamab in myeloma is not planned, but studies are underway in autoimmune conditions. This trial was registered at <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> as #NCT03439280.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma 多发性骨髓瘤的来那度胺、伊沙佐米或达拉曲单抗维持疗法
Pub Date : 2024-09-16 DOI: 10.1016/j.bneo.2024.100042
Eunice Lai ∗ , Yu Yang Soon ∗ , Ainsley Ryan Yan Bin Lee , Shi Yin Wong , Cinnie Yentia Soekojo , Melissa Ooi , Wee Joo Chng , Sanjay de Mel

Abstract

Lenalidomide, ixazomib, and daratumumab have been proposed as maintenance therapies for patients with newly diagnosed multiple myeloma (MM; NDMM). There are, however, no randomized controlled trials (RCTs) comparing them. We conducted a network meta-analysis (NMA) of RCTs comparing these agents against placebo in NDMM. A Bayesian NMA model was used to assess the relative effects of competing treatments on progression-free survival (PFS) and overall survival (OS) in 9 studies including 4115 patients with transplant-eligible MM (TEMM) and 1689 patients with non–transplant-eligible MM (NTEMM). Lenalidomide and daratumumab but not ixazomib were associated with improved PFS compared with placebo in patients with TEMM (lenalidomide [hazard ratio (HR), 0.46; 95% credible interval (CrI), 0.36-0.56]; daratumumab [HR, 0.49; 95% Crl, 0.32-0.76]; and ixazomib [HR, 0.72; 95% CrI, 0.46-1.12]) and those with NTEMM (lenalidomide [HR, 0.46; 95% CrI, 0.29-0.75] and ixazomib [HR, 0.69; 95% CrI, 0.43-1.18]). The PFS benefit for daratumumab was present regardless of whether daratumumab-based induction therapy was received. None of the agents showed an OS benefit, and PFS benefits were not seen in patients with high-risk cytogenetics. Lenalidomide was associated with second malignancies, ixazomib with thrombocytopenia, and daratumumab with pneumonia. We propose that lenalidomide remains the maintenance therapy of choice for NDMM.
摘要 来那度胺、伊沙佐米和达拉曲单抗已被提议作为新诊断多发性骨髓瘤(MM;NDMM)患者的维持疗法。然而,目前还没有随机对照试验(RCT)对它们进行比较。我们对在 NDMM 中比较这些药物与安慰剂的 RCT 进行了网络荟萃分析(NMA)。我们使用贝叶斯NMA模型评估了9项研究中竞争治疗对无进展生存期(PFS)和总生存期(OS)的相对影响,这些研究包括4115名符合移植条件的MM(TEMM)患者和1689名不符合移植条件的MM(NTEMM)患者。与安慰剂相比,来那度胺和达拉曲单抗改善了TEMM患者的PFS(来那度胺[危险比(HR),0.46;95%可信区间(CrI),0.36-0.56];daratumumab[HR,0.49;95% Crl,0.32-0.76];ixazomib[HR,0.72;95% CrI,0.46-1.12]])和NTEMM患者(来那度胺[HR,0.46;95% CrI,0.29-0.75]和ixazomib[HR,0.69;95% CrI,0.43-1.18])。无论是否接受了基于达拉土单抗的诱导治疗,达拉土单抗的PFS获益都是存在的。没有一种药物显示出OS获益,高危细胞遗传学患者也没有PFS获益。来那度胺与二次恶性肿瘤有关,伊沙佐米与血小板减少有关,达拉土单抗与肺炎有关。我们建议来那度胺仍是NDMM的首选维持疗法。
{"title":"Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma","authors":"Eunice Lai ∗ ,&nbsp;Yu Yang Soon ∗ ,&nbsp;Ainsley Ryan Yan Bin Lee ,&nbsp;Shi Yin Wong ,&nbsp;Cinnie Yentia Soekojo ,&nbsp;Melissa Ooi ,&nbsp;Wee Joo Chng ,&nbsp;Sanjay de Mel","doi":"10.1016/j.bneo.2024.100042","DOIUrl":"10.1016/j.bneo.2024.100042","url":null,"abstract":"<div><h3>Abstract</h3><div>Lenalidomide, ixazomib, and daratumumab have been proposed as maintenance therapies for patients with newly diagnosed multiple myeloma (MM; NDMM). There are, however, no randomized controlled trials (RCTs) comparing them. We conducted a network meta-analysis (NMA) of RCTs comparing these agents against placebo in NDMM. A Bayesian NMA model was used to assess the relative effects of competing treatments on progression-free survival (PFS) and overall survival (OS) in 9 studies including 4115 patients with transplant-eligible MM (TEMM) and 1689 patients with non–transplant-eligible MM (NTEMM). Lenalidomide and daratumumab but not ixazomib were associated with improved PFS compared with placebo in patients with TEMM (lenalidomide [hazard ratio (HR), 0.46; 95% credible interval (CrI), 0.36-0.56]; daratumumab [HR, 0.49; 95% Crl, 0.32-0.76]; and ixazomib [HR, 0.72; 95% CrI, 0.46-1.12]) and those with NTEMM (lenalidomide [HR, 0.46; 95% CrI, 0.29-0.75] and ixazomib [HR, 0.69; 95% CrI, 0.43-1.18]). The PFS benefit for daratumumab was present regardless of whether daratumumab-based induction therapy was received. None of the agents showed an OS benefit, and PFS benefits were not seen in patients with high-risk cytogenetics. Lenalidomide was associated with second malignancies, ixazomib with thrombocytopenia, and daratumumab with pneumonia. We propose that lenalidomide remains the maintenance therapy of choice for NDMM.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142573253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis BIRC5 上调可提高 DNMT3A 突变 T-ALL 细胞的存活率和发病率
Pub Date : 2024-09-05 DOI: 10.1016/j.bneo.2024.100040
Wangisa Dunuwille , William C. Wilson , Hassan Bjeije , Nancy Issa , Wentao Han , Tyler M. Parsons , Andrew L. Young , Infencia Xavier Raj , Aishwarya Krishnan , Tarang Gaur , Eunice S. Wang , Andrew P. Weng , Matthew C. Stubbs , Hamza Celik , Amanda F. Cashen , John R. Edwards , Grant A. Challen

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic neoplasm. Although the prognosis of pediatric T-ALL has improved with intensified chemotherapy regimens, this benefit has largely not translated to the adult T-ALL population. Development of new treatments requires understanding the mechanisms driven by specific mutations. DNMT3A mutations are identified in ∼10% to 18% of adult patients with T-ALL and are associated with poor clinical outcomes. Here, using primary human specimens, we show that cells from patients with T-ALL with DNMT3A mutations are resistant to apoptosis and certain chemotherapies. Elevated JAK/STAT signaling drove prosurvival programs in patients with mutant DNMT3A, and JAK/STAT inhibition restored sensitivity to chemotherapy. The prosurvival gene BIRC5 was upregulated in patients with DNMT3A-mutant T-ALL, and these cells were specifically sensitive to the Baculoviral IAP Repeat Containing 5 (BIRC5) inhibitor YM155. Genetic inhibition of BIRC5 in vivo lead to rapid depletion of DNMT3A-mutant T-ALL cells in patient-derived xenografts, positioning BIRC5 as a precision medicine target for these patients.
摘要T细胞急性淋巴细胞白血病(T-ALL)是一种侵袭性造血肿瘤。虽然小儿 T-ALL 的预后随着化疗方案的加强而有所改善,但这种益处在很大程度上并没有转化到成人 T-ALL 群体中。开发新的治疗方法需要了解特定突变的驱动机制。在10%到18%的成人T-ALL患者中发现了DNMT3A突变,而且与不良的临床预后有关。在这里,我们利用原代人类标本表明,来自T-ALL患者的细胞如果存在DNMT3A突变,就会对细胞凋亡和某些化疗产生耐药性。JAK/STAT信号的升高推动了DNMT3A突变患者的促生存程序,抑制JAK/STAT可恢复对化疗的敏感性。在DNMT3A突变的T-ALL患者中,前生存基因BIRC5上调,这些细胞对含有IAP重复序列5的杆状病毒(Baculoviral IAP Repeat Containing 5,BIRC5)抑制剂YM155特别敏感。在体内对BIRC5进行基因抑制可迅速清除患者异种移植中的DNMT3A突变T-ALL细胞,从而将BIRC5定位为这些患者的精准医疗靶点。
{"title":"BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis","authors":"Wangisa Dunuwille ,&nbsp;William C. Wilson ,&nbsp;Hassan Bjeije ,&nbsp;Nancy Issa ,&nbsp;Wentao Han ,&nbsp;Tyler M. Parsons ,&nbsp;Andrew L. Young ,&nbsp;Infencia Xavier Raj ,&nbsp;Aishwarya Krishnan ,&nbsp;Tarang Gaur ,&nbsp;Eunice S. Wang ,&nbsp;Andrew P. Weng ,&nbsp;Matthew C. Stubbs ,&nbsp;Hamza Celik ,&nbsp;Amanda F. Cashen ,&nbsp;John R. Edwards ,&nbsp;Grant A. Challen","doi":"10.1016/j.bneo.2024.100040","DOIUrl":"10.1016/j.bneo.2024.100040","url":null,"abstract":"<div><h3>Abstract</h3><div>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic neoplasm. Although the prognosis of pediatric T-ALL has improved with intensified chemotherapy regimens, this benefit has largely not translated to the adult T-ALL population. Development of new treatments requires understanding the mechanisms driven by specific mutations. <em>DNMT3A</em> mutations are identified in ∼10% to 18% of adult patients with T-ALL and are associated with poor clinical outcomes. Here, using primary human specimens, we show that cells from patients with T-ALL with <em>DNMT3A</em> mutations are resistant to apoptosis and certain chemotherapies. Elevated JAK/STAT signaling drove prosurvival programs in patients with mutant <em>DNMT3A</em>, and JAK/STAT inhibition restored sensitivity to chemotherapy. The prosurvival gene <em>BIRC5</em> was upregulated in patients with <em>DNMT3A</em>-mutant T-ALL, and these cells were specifically sensitive to the Baculoviral IAP Repeat Containing 5 (BIRC5) inhibitor YM155. Genetic inhibition of <em>BIRC5</em> in vivo lead to rapid depletion of <em>DNMT3A</em>-mutant T-ALL cells in patient-derived xenografts, positioning BIRC5 as a precision medicine target for these patients.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice 伊布替尼和 venetoclax 联合治疗慢性淋巴细胞白血病:实践中的协同作用
Pub Date : 2024-09-01 DOI: 10.1016/j.bneo.2024.100034
Natalia Timofeeva , Nitin Jain , Varsha Gandhi

Abstract

The combination of ibrutinib and venetoclax has emerged as a promising therapeutic strategy for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations demonstrated a synergistic antitumor effect through multiple mechanisms, providing a robust foundation for translating this regimen into clinical trials. Beyond the dual inhibition by 2 small molecules, another innovative concept being tested with this combination is the use of measurable residual disease (MRD)–driven treatment vs fixed-duration treatment to meet the escalating demand for oral, convenient, cost-effective, and time-limited therapeutic approaches. The clinical translation of this combination has yielded remarkable outcomes with significant improvements in the progression-free survival and overall survival rates for both treatment-naïve patients and those with relapsed/refractory CLL. Notably, a substantial proportion of patients achieved undetectable MRD. Clinical trial updates following the initial published results have shown consistency and durability of responses over time. In this review, the initial investigator-initiated trial results for ibrutinib and venetoclax are discussed, several multicenter clinical trial designs and outcomes are examined, variables such as chromosome 17p deletion that influence treatment responses are addressed, and the safety of the regimen is discussed. In addition, we reviewed the usage of this combination in other B-cell malignancies and discussed how current knowledge can be used for shaping the future CLL treatment regimens.

摘要 ibrutinib和venetoclax联合治疗慢性淋巴细胞白血病(CLL)已成为一种很有前景的治疗策略。临床前研究表明,这两种药物通过多种机制产生协同抗肿瘤作用,为将这一治疗方案转化为临床试验奠定了坚实的基础。除了两种小分子的双重抑制作用外,这种组合疗法的另一个创新理念是使用可测量残留疾病(MRD)驱动的治疗与固定疗程的治疗,以满足对口服、方便、经济、有时限的治疗方法不断升级的需求。这种组合疗法的临床应用取得了显著成果,治疗无效患者和复发/难治性 CLL 患者的无进展生存率和总生存率都得到了明显改善。值得注意的是,相当一部分患者的MRD检测不到。在首次公布结果后,临床试验更新显示,随着时间的推移,反应具有一致性和持久性。在这篇综述中,我们讨论了研究者发起的伊布替尼和 venetoclax 最初的试验结果,研究了几项多中心临床试验的设计和结果,探讨了影响治疗反应的染色体 17p 缺失等变量,并讨论了治疗方案的安全性。此外,我们还回顾了这一联合疗法在其他 B 细胞恶性肿瘤中的应用,并讨论了如何利用现有知识制定未来的 CLL 治疗方案。
{"title":"Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice","authors":"Natalia Timofeeva ,&nbsp;Nitin Jain ,&nbsp;Varsha Gandhi","doi":"10.1016/j.bneo.2024.100034","DOIUrl":"10.1016/j.bneo.2024.100034","url":null,"abstract":"<div><h3>Abstract</h3><p>The combination of ibrutinib and venetoclax has emerged as a promising therapeutic strategy for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations demonstrated a synergistic antitumor effect through multiple mechanisms, providing a robust foundation for translating this regimen into clinical trials. Beyond the dual inhibition by 2 small molecules, another innovative concept being tested with this combination is the use of measurable residual disease (MRD)–driven treatment vs fixed-duration treatment to meet the escalating demand for oral, convenient, cost-effective, and time-limited therapeutic approaches. The clinical translation of this combination has yielded remarkable outcomes with significant improvements in the progression-free survival and overall survival rates for both treatment-naïve patients and those with relapsed/refractory CLL. Notably, a substantial proportion of patients achieved undetectable MRD. Clinical trial updates following the initial published results have shown consistency and durability of responses over time. In this review, the initial investigator-initiated trial results for ibrutinib and venetoclax are discussed, several multicenter clinical trial designs and outcomes are examined, variables such as chromosome 17p deletion that influence treatment responses are addressed, and the safety of the regimen is discussed. In addition, we reviewed the usage of this combination in other B-cell malignancies and discussed how current knowledge can be used for shaping the future CLL treatment regimens.</p></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 3","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950328024000347/pdfft?md5=6d685af44e4971629738466491360299&pid=1-s2.0-S2950328024000347-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study 加强使用 L-天冬酰胺酶可显著改善 AYA ALL 的预后:FBMTG前瞻性MRD2014研究
Pub Date : 2024-09-01 DOI: 10.1016/j.bneo.2024.100033
Koji Nagafuji , Toshihiro Miyamoto , Tetsuya Eto , Tomohiko Kamimura , Koji Kato , Yasuhiko Miyazaki , Atsushi Wake , Kentaro Kohno , Ken Takase , Yutaka Imamura , Naoyuki Uchida , Kazuki Tanimoto , Noriaki Kawano , Toshiro Kurokawa , Yukio Kondo , Yoshikiyo Ito , Tomoaki Fujisaki , Junichi Tsukada , Koji Yonemoto , Toshinori Hori , Koichi Akashi

Abstract

The enhanced utilization of native L-asparaginase (L-Asp) aims to improve treatment outcomes for adult patients with non-Philadelphia chromosome (Ph) acute lymphoblastic leukemia (ALL). In this measurable residual disease 2014 (MRD2014) study, we modified our protocol to include an augmented dose of native L-Asp. Compared with former MRD2008, the total dose of L-Asp was raised from 36 000 U/m2 to 232 000 U/m2 in patients aged 16 to 35 and from 36 000 U/m2 to 132 000 U/m2 in patients aged 36 to 65 years. Adult patients with ALL were enrolled between January 2014 and December 2019 based on the following eligibility criteria: non-L3 ALL, age 16 to 65 years, Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate liver and kidney functions (serum bilirubin ≤ 2.0 mg/dL; serum creatinine ≤ 2.0 mg/dL). The median follow-up time was 1128 days (range, 35-2400). A total of 81 patients with non-Ph ALL (40 males and 41 females; median age, 39 years [range, 16-64]) in whom MRD status was assessed were included. Complete remission was achieved in 72 patients (89%). The probability of 3-year event-free survival (EFS) and overall survival (OS) in these patients were 55% and 72%, respectively. The outcomes for patients aged 16 to 35 years demonstrated remarkable improvement. The 3-year EFS of MRD2008 at 45% significantly increased to 71% for MRD2014. Our study unequivocally demonstrated the beneficial effects of augmented use of L-Asp in this adolescent and young adult population. This trial was registered at UMIN Clinical Trials Registry as #UMIN000012382.

摘要提高原生L-天冬酰胺酶(L-Asp)的使用率旨在改善非费城染色体(Ph)急性淋巴细胞白血病(ALL)成人患者的治疗效果。在这项可测量残留疾病2014(MRD2014)研究中,我们修改了治疗方案,增加了原生L-Asp的剂量。与之前的MRD2008相比,16至35岁患者的L-Asp总剂量从36000 U/m2提高到232000 U/m2,36至65岁患者的L-Asp总剂量从36000 U/m2提高到132000 U/m2。2014年1月至2019年12月期间,成人ALL患者根据以下资格标准入组:非L3 ALL、年龄16至65岁、东部合作肿瘤学组表现状态为0至2、肝肾功能正常(血清胆红素≤2.0 mg/dL;血清肌酐≤2.0 mg/dL)。中位随访时间为 1128 天(35-2400 天不等)。共纳入了81例评估了MRD状态的非Ph ALL患者(男性40例,女性41例;中位年龄39岁[16-64岁])。72名患者(89%)获得了完全缓解。这些患者的 3 年无事件生存率(EFS)和总生存率(OS)分别为 55% 和 72%。16 至 35 岁患者的疗效显著改善。MRD2008的3年无事件生存率为45%,而MRD2014的3年无事件生存率则大幅提高到71%。我们的研究明确显示,在青少年和年轻成年人群体中增加使用 L-Asp 有益。该试验已在 UMIN 临床试验注册中心注册,注册号为 #UMIN000012382。
{"title":"Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study","authors":"Koji Nagafuji ,&nbsp;Toshihiro Miyamoto ,&nbsp;Tetsuya Eto ,&nbsp;Tomohiko Kamimura ,&nbsp;Koji Kato ,&nbsp;Yasuhiko Miyazaki ,&nbsp;Atsushi Wake ,&nbsp;Kentaro Kohno ,&nbsp;Ken Takase ,&nbsp;Yutaka Imamura ,&nbsp;Naoyuki Uchida ,&nbsp;Kazuki Tanimoto ,&nbsp;Noriaki Kawano ,&nbsp;Toshiro Kurokawa ,&nbsp;Yukio Kondo ,&nbsp;Yoshikiyo Ito ,&nbsp;Tomoaki Fujisaki ,&nbsp;Junichi Tsukada ,&nbsp;Koji Yonemoto ,&nbsp;Toshinori Hori ,&nbsp;Koichi Akashi","doi":"10.1016/j.bneo.2024.100033","DOIUrl":"10.1016/j.bneo.2024.100033","url":null,"abstract":"<div><h3>Abstract</h3><p>The enhanced utilization of native L-asparaginase (L-Asp) aims to improve treatment outcomes for adult patients with non-Philadelphia chromosome (Ph) acute lymphoblastic leukemia (ALL). In this measurable residual disease 2014 (MRD2014) study, we modified our protocol to include an augmented dose of native L-Asp. Compared with former MRD2008, the total dose of L-Asp was raised from 36 000 U/m<sup>2</sup> to 232 000 U/m<sup>2</sup> in patients aged 16 to 35 and from 36 000 U/m<sup>2</sup> to 132 000 U/m<sup>2</sup> in patients aged 36 to 65 years. Adult patients with ALL were enrolled between January 2014 and December 2019 based on the following eligibility criteria: non-L3 ALL, age 16 to 65 years, Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate liver and kidney functions (serum bilirubin ≤ 2.0 mg/dL; serum creatinine ≤ 2.0 mg/dL). The median follow-up time was 1128 days (range, 35-2400). A total of 81 patients with non-Ph ALL (40 males and 41 females; median age, 39 years [range, 16-64]) in whom MRD status was assessed were included. Complete remission was achieved in 72 patients (89%). The probability of 3-year event-free survival (EFS) and overall survival (OS) in these patients were 55% and 72%, respectively. The outcomes for patients aged 16 to 35 years demonstrated remarkable improvement. The 3-year EFS of MRD2008 at 45% significantly increased to 71% for MRD2014. Our study unequivocally demonstrated the beneficial effects of augmented use of L-Asp in this adolescent and young adult population. This trial was registered at UMIN Clinical Trials Registry as #UMIN000012382.</p></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 3","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950328024000335/pdfft?md5=bbf499ae9c9b69c23bb21aa6d69f4833&pid=1-s2.0-S2950328024000335-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Neoplasia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1